Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435862 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
A Phase 2 study of Non-Proliferative Diabetic Retinopathy, sponsored by Allegro Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 12
- Study locations
NCT02435862 is a Phase 2 study of Non-Proliferative Diabetic Retinopathy that has completed, run by Allegro Ophthalmics. The registered enrollment target is 105 participants, below the 323-participant average among 4 other Non-Proliferative Diabetic Retinopathy trials with a reported enrollment target (67% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT02435862, a Phase 2 study of Non-Proliferative Diabetic Retinopathy, has completed, sponsored by Allegro Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
Conditions Studied
Interventions
- DRUG 1.0mg Luminate®
- DRUG 2.0mg Luminate®
- DRUG 3.0mg Luminate®
- OTHER Balanced Salt Solution for intravitreal injection in 0.10cc
Study Locations (12)
Texas
- Retina Research Institute Of Texas - Abilene
- Austin Retina Associates - Austin
- Valley Retina Institute - McAllen
- Medical Center Ophthalmology Associates - San Antonio
California
- Northern California Retina Vitreous Associates - Mountain View
- UCI Medical Center - Orange
Connecticut
- New England Retina Associates - New London
Florida
- Center for Retina and Macular Disease - Lakeland
Illinois
- Illinois Retina Center - Springfield
Indiana
- Midwest Eye Institute - Indianapolis
Virginia
- The Retina Group of Washington - Fairfax
Washington
- Spokane Eye Clinical Research - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2017-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435862
The ClinicalTrials.gov registry entry for NCT02435862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 4 other Non-Proliferative Diabetic Retinopathy trials with a reported enrollment target (67% lower). The listed sponsor is Allegro Ophthalmics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 4 interventions - of which 1.0mg Luminate® is the first listed.
NCT02435862 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02435862 about?
NCT02435862 is a clinical study titled "A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy". A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
What is the current status of trial NCT02435862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2015-02-01. Estimated completion is 2017-08-10.
What conditions does trial NCT02435862 study?
This clinical trial studies the following conditions: Non-Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT02435862?
The interventions under investigation include: 1.0mg Luminate® (DRUG), 2.0mg Luminate® (DRUG), 3.0mg Luminate® (DRUG), Balanced Salt Solution for intravitreal injection in 0.10cc (OTHER).
Who is sponsoring clinical trial NCT02435862?
This trial is sponsored by Allegro Ophthalmics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02435862 being conducted?
This trial has 12 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of Faricimab in Patients With NPDR
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
RECRUITING · Phase 3
-
Diabetes Visual Function Supplement Study
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.